(Q36669045)

15 August 2017

1 reference

title

A new era in phosphate binder therapy: what are the options? (English)

1 reference

15 August 2017

Salusky IB

1

1 reference

15 August 2017

language of work or name

1 reference

1 December 2006

1 reference

Kidney International. Supplement

15 August 2017

published in

1 reference

15 August 2017

issue

105

1 reference

15 August 2017

page(s)

S10-5

1 reference

Phosphate binder usage in kidney failure patients

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

A comparison of clinically useful phosphorus binders for patients with chronic kidney failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Nocturnal home haemodialysis: an update on a 5-year experience.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Calcium phosphate metabolism and bone mineral density with nocturnal hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Accumulation of metals and minerals from phosphate binders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

The clinical impact of aluminium overload in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Aluminium toxicokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Citrate: a major factor in the toxicity of orally administered aluminum compounds

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Control of hyperphosphatemia among patients with ESRD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Evidence for abnormal calcium homeostasis in patients with adynamic bone disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Arterial stiffening and vascular calcifications in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

The spectrum of bone disease in end-stage renal failure--an evolving disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Arterial calcifications and bone histomorphometry in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Progressive accumulation of lanthanum in the liver of normal and uremic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5001997

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5001997

0 references

1 reference